

# Source details

## Pan African Medical Journal

Open Access ⓘ

Scopus coverage years: from 2010 to 2022

Publisher: Pan African Medical Journal

ISSN: 1937-8688

Subject area: Medicine: General Medicine

Source type: Journal

CiteScore 2021

1.0 ⓘ

SJR 2021

0.283 ⓘ

SNIP 2021

0.509 ⓘ

[View all documents >](#)

[Set document alert](#)

[Save to source list](#) [Source Homepage](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

### i Improved CiteScore methodology ✕

CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021 ▼

$$1.0 = \frac{3,291 \text{ Citations 2018 - 2021}}{3,267 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022 ⓘ

$$1.4 = \frac{4,573 \text{ Citations to date}}{3,344 \text{ Documents to date}}$$

Last updated on 05 January, 2023 • Updated monthly

## CiteScore rank 2021 ⓘ

Category	Rank	Percentile
Medicine		
General Medicine	#488/826	40th

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site ↗](#)



### Published with Hindawi

Math, Eng., & Comp. Sci. Articles Are Peer Reviewed, Open Access Available Online


Hindawi



## Pan African Medical Journal

**COUNTRY**

Nigeria



**SUBJECT AREA AND CATEGORY**

Medicine  
Medicine (miscellaneous)

**PUBLISHER**

**H-INDEX**

**36**



**PUBLICATION TYPE**

Journals

**ISSN**

19378688

**COVERAGE**

2010-2021

**INFORMATION**

- [Homepage](#)
- [How to publish in this journal](#)
- [editor@panafrican-med-journal.com](mailto:editor@panafrican-med-journal.com)

Published with  
Hindawi



Open

**SCOPE**

We believe that scientific work done in Africa should be rapidly and freely made available to all researchers worldwide. Aim: To create, stimulate and perpetuate a culture of information sharing and publishing amongst researchers and other health actors of the African health scene in ways that will contribute to availability of health information, better understanding of Africa specificities and overall, to improve health outcomes of the people on the continent. Scope: We publish original scientific research on clinical, public health, social, political, economic and all other factors affecting the health of populations in Africa.

 Join the conversation about this journal

### Published with Hindawi

Math, Eng., & Comp. Sci. Articles Are Peer Reviewed, Open Access Ar Available Online

Hindawi

Quartiles

#### FIND SIMILAR JOURNALS

options

<p>1 <b>BMC Research Notes</b></p> <p>GBR</p> <p><b>62%</b> similarity</p>	<p>2 <b>Malawi Medical Journal</b></p> <p>MWI</p> <p><b>57%</b> similarity</p>	<p>3 <b>Clinical Epidemiology and Global Health</b></p> <p>NLD</p> <p><b>56%</b> similarity</p>	<p>4 <b>Iranian Journal of Public Health</b></p> <p>IRN</p> <p><b>53%</b> similarity</p>	<p>5 <b>Open Public Health Journal</b></p> <p>NLD</p> <p><b>52%</b> similarity</p>
--	--	---	--	--

### Published with Hindawi

Math, Eng., & Comp. Sci. Articles Are Peer Reviewed, Open Access Ar Available Online

Hindawi



**Pan African Medical Journal**

← Show this widget in your own website

Q3  
Medicine (miscellaneous)  
best quartile

SJR 2021  
0.28

powered by scimagojr.com

Just copy the code below and paste within your html code:

```
<a href="https://www.scimi
```



Explore, visually communicate and make sense of data with our **new data visualization tool**.





## Archives of the Pan African Medical Journal

[Volume 44 \(54\)](#)

[Volume 43 \(216\)](#)

[Volume 42 \(324\)](#)

[Outcomes and predictors of tuberculosis mortality in Kweneng West District, Botswana: a retrospective cohort study \[Research\].](#)

Keatlaretse Siamisang, Goabaone Rankgoane-Pono, Tumisang Malebo Madisa, Tantamika Mudiayi, John Thato Tlhakanelo

*PAMJ. Volume 42 (1). 02 May 2022 | PDF*

[Syndrome d'Ogilvie, une complication rare de la chirurgie du canal lombaire étroit: à propos de deux cas et revue de la littérature \[Case report\].](#)

Gbètoho Fortuné Gankpé, Laurent Do, Mohammed Rabhi

*PAMJ. Volume 42 (2). 04 May 2022 | PDF*

[Cataracte post traumatique rompue négligée \[Images in clinical medicine\].](#)

Loubna El Kaissoumi, Basma Mrini

*PAMJ. Volume 42 (3). 04 May 2022 | PDF*

[Attitudes towards interprofessional education and associated factors among faculty at the college of health sciences in a public university in Kenya: a cross-sectional study \[Research\].](#)

Rosemary Kawira Kithuci, Drusilla Makworo, Albanus Mutisya, Justus Simba, Patrick Mburugu

*PAMJ. Volume 42 (4). 05 May 2022 | PDF*

[Prenatal diagnosis and pregnancy outcome of acardiac amorphus twin \[Images in clinical medicine\].](#)

Mahdi Farhati, Abir Karoui

*PAMJ. Volume 42 (5). 05 May 2022 | PDF*

[Emergence of universal antiretroviral therapy coverage in South Africa: applying the advocacy coalition framework to refine the narratives and inform epidemic responses \[Essay\].](#)

Benjamin Momo Kadia, Christian Akem Dimala, Kevin Pene Njefi

*PAMJ. Volume 42 (6). 05 May 2022 | PDF*

[Hemostatic instantaneous coagulation on echocardiogram: a defining](#)

[feature of the last heartbeat \(a case report\) \[Case report\].](#)

Tokunbo David Gbadebo, Daniel Antwi-Amoabeng, Ademola Abiose  
*PAMJ. Volume 42 (7). 05 May 2022 | PDF*

[Knowledge, attitude and premarital screening practices for sickle cell disease among young unmarried adults in an urban community in Lagos, Nigeria \[Research\].](#)

Esther Oluwakemi Oluwole, Chibuike Davidson Okoye, Adedoyin Oyeyimika  
Ogunyemi, Olusola Festus Olowoselu, Olufemi Abiola Oyedeji  
*PAMJ. Volume 42 (8). 06 May 2022 | PDF*

[Connaissances, attitudes et pratiques relatives à la cataracte et au glaucome dans la population de Conakry en Guinée \[Research\].](#)

Maxime Dantouma Sovogui, Pierre Louis Lamah, Christophe Zoumanigui, Tamba Elie Tolno, Kokou Vonor  
*PAMJ. Volume 42 (9). 06 May 2022 | PDF*

[Surgical excision of vaginal cysts presenting as pelvic organ prolapse: a case series \[Case series\].](#)

Sofia Tsiapakidou, Iakovos Theodoulidis, Grigoris Grimbizis, Themistoklis Mikos  
*PAMJ. Volume 42 (10). 06 May 2022 | PDF*

[Anencephaly: a rare clinical image \[Images in clinical medicine\].](#)

Mayur Bhaskar Wanjari, Tejaswee Lohakare  
*PAMJ. Volume 42 (11). 06 May 2022 | PDF*

[Two-week prevalence of acute diarrhea and associated factors among under five year's children in Simada Woreda, South Gondar Zone, Northwest Ethiopia, 2021: a multi-central community based cross-sectional study \[Research\].](#)

Dejen Getaneh Feleke, Ermias Sisay Chanie, Fitalew Tadele Admasu, Shimels Bahir, Abraham Tsedalu Amare, Halemicheal Kindie Abate  
*PAMJ. Volume 42 (12). 07 May 2022 | PDF*

[Characterization and drug susceptibility pattern of \*Salmonella\* and \*Shigella\* in children below five years: a crosssectional study conducted in Lodwar, Turkana County, in Northern Kenya \[Research\].](#)

Simion Kipchirchir Leting, Stanslaus Kiilu Musyoki, Geoffrey Kattam Maiyoh  
*PAMJ. Volume 42 (13). 09 May 2022 | PDF*

[Clofazimine induced pigmentation in leprosy patches \[Images in clinical medicine\].](#)

Samiksha Deepak Chavhan, Sugat Jawade  
*PAMJ. Volume 42 (14). 09 May 2022 | PDF*

[Negative-pressure pulmonary edema after mammoplasty: a case report \[Case report\].](#)

Didem Onk, Onur Işık, Faruk Subaşı, Soner Karaali, Ufuk Kuyrukluıldız  
*PAMJ. Volume 42 (15). 09 May 2022 | PDF*

[The putty kidney: a classic sign from past in genitourinary radiology \[Images in clinical medicine\].](#)

Savas Deftereos, Soultana Foutzitzzi  
*PAMJ. Volume 42 (16). 09 May 2022 | PDF*

[Dysplasie septo optique plus: à propos d'un cas \[Case report\].](#)

[pregnant women \[Research\].](#)

Chidozie Emmanuel Mbada, Dolapo Adeola Ojo, Olabisi Aderonke Akinwande, Okechukwu Ernest Orji, Adebajo Babalola Adeyemi, Kikelomo Aboyowa Mbada, Esther Kikelomo Afolabi

*PAMJ. Volume 42 (321). 30 Aug 2022 | PDF*

[Expression of cytokeratin-7 and cytokeratin-19 on newborn mice induced rhesus rotavirus as biliary atresia model \[Research\].](#)

Bagus Setyoboedi, Ahmad Rofii, Anang Endaryanto, Sjamsul Arief

*PAMJ. Volume 42 (322). 31 Aug 2022 | PDF*

[Facteurs prédictifs de l'encéphalopathie hépatique au cours de l'atteinte hépatique aigüe sévère \[Research\].](#)

Amal Khsiba, Samir Bradai, Moufida Mahmoudi, Asma Ben Mohamed, Mouna Medhioub, Lamine Hamzaoui, Mohamed Mousadek Azouz

*PAMJ. Volume 42 (323). 31 Aug 2022 | PDF*

[Case of leprosy in child \[Images in clinical medicine\].](#)

Archana Thaware, Renu Rathi

*PAMJ. Volume 42 (324). 31 Aug 2022 | PDF*

[Volume 41 \(350\)](#)

[Volume 40 \(268\)](#)

[Volume 39 \(287\)](#)

[Volume 38 \(414\)](#)

[Volume 37 \(391\)](#)

[Volume 36 \(385\)](#)

[Volume 35 \(142\)](#)

[Volume 34 \(217\)](#)

[Volume 33 \(330\)](#)

[Volume 32 \(218\)](#)

[Volume 31 \(251\)](#)

[Volume 30 \(306\)](#)

[Volume 29 \(229\)](#)

[Volume 28 \(318\)](#)

Advertise with the PAMJ



Search..

Go

## Editorial board of PAMJ (Year 2022)

### Managing Editors

**Raoul Kamadjeu** [\[PubMed\]](#)

PAMJ, **Kenya** (Public Health, Epidemiology, Immunization, Health Emergencies)

**Landry Tsague** [\[PubMed\]](#)

PAMJ, UNICEF Senegal, **Senegal** (Public Health, HIV)

**Sheba Gitta** [\[PubMed\]](#)

Public health consultant, **Uganda** (Public Health, Epidemiology)

### Editorial board member

**Jean Claude Mbanya** [\[PubMed\]](#)

Faculty of Medicine and Biomedical Sciences, Yaounde University 1, Yaounde, **Cameroon** (Epidemiology, Endocrinology, Diabetes)

**David G. Kleinbaum** [\[PubMed\]](#)

Rollins School of Public Health, Emory University, **United States** (Epidemiology, HIV, Global Health)

**Deborah McFarland** [\[PubMed\]](#)

Rollins School of Public Health, Emory University, **United States** (Global Health, Health policy)

**Leopold Zekeng** [\[PubMed\]](#)

UNAIDS, **Tanzania, United Republic Of** (Global Health, Health Policy, HIV)

**Abdou Salam Gueye** [\[PubMed\]](#)

WHO, **Senegal** (Global Health, Health policy)

**André Pascal Kengne** [\[PubMed\]](#)

University of Cape Town, South Africa Director, South African Medical Research Council, **South Africa** (Global Health, Chronic Diseases Epidemiology)

**Samuel Kingue** [\[PubMed\]](#)

Faculty of Medicine and Biomedical Sciences, Yaounde University 1, Yaounde, **Cameroon** (Chronic Diseases epidemiology, Cardiology)

**Mathurin Tejiokem** [\[PubMed\]](#)

Centre Pasteur du Cameroun, **Cameroon** (Epidemiology, Virology)

**Amha Mekasha** [\[PubMed\]](#)

Addis Ababa University, **Ethiopia** (Child health, Medical Ethics, Pediatrics)

**Ali Mtiraoui** [\[PubMed\]](#)

Universite de Tunis (Retraite), **Tunisia** (Family medicine)

**Ramesh Krishnamurthy** [\[PubMed\]](#)

World Health Organization, **Switzerland** (Public Health Informatics, Health Metrics)

**Richard Njouom** [\[PubMed\]](#)

Centre Pasteur du Cameroun, **Cameroon** (Virology)

**Felix Ndagije** [\[PubMed\]](#)

Centers for Disease Control and Prevention/GAP, **Lesotho** (Epidemiology, Public Health, HIV)

**Abdoul Aziz Kasse** [\[PubMed\]](#)

Institut du Cancer, Universite Cheikh Anta DIOP, **Senegal** (Cancerology)

**Estelle Anaelle Nguewo** [\[PubMed\]](#)

University of applied sciences Sigmaringen, **Germany** (Public Health, Nutrition)

**Gilbert Tene** [\[PubMed\]](#)

QED Group LLC/US Centers for Disease Control and Prevention (CDC) , **Cameroon** (Epidemiology HIV)

**Serge Tchamgoue** [\[PubMed\]](#)

Centre Hospitalier de Libourne, **France** (Infectious diseases)

**Jean B. Nachega** [\[PubMed\]](#)

Faculty of Health Sciences, Stellenbosch University, **South Africa** (Global Health, Health Economy)

**Caroline W. Kabiru** [\[PubMed\]](#)

African Population and Health Research Center, **Kenya** (Public Health, Epidemiology, Population Health)

**Robert Davis** [\[PubMed\]](#)

Rainbarrel Communications, **United States** (Immunization)

**Frank Edwin** [\[PubMed\]](#)

National Cardiothoracic Centre, Korle Bu, **Ghana** (Cardio-thoracic Surgery)

**Takuva Simbarashe** [\[PubMed\]](#)

University of Pretoria/Universiteit van Pretoria, HIV Vaccine Trials Network at Fred Hutch, **South Africa** (Public Health, Epidemiology, HIV)

**Ambroise Wonkam** [\[PubMed\]](#)

Faculty of Health Sciences, Division of Human Genetics, University of Cape Town, **South Africa** (Population Genetics)

**Mohamed Chikri** [\[PubMed\]](#)

Faculte de Medecine et de Pharmacie de Fes, Laboratoire de Biochimie et Biologie Moleculaire, **Morocco** (Pharmacology)

**Benford Mafuvadze** [\[PubMed\]](#)

Department of Biomedical Science, College of Veterinary Sciences, University of Missouri, **United States** (Veterinary Medicine)

**David Lagoro Kitara** [\[PubMed\]](#)

Department of Surgery, Gulu University, Faculty of Medicine, **Uganda** (Surgery)

**Benjamin Longo-Mbenza** [\[PubMed\]](#)

Walter Sisulu University, Faculty of Health Sciences, **South Africa** (Cardiology, Patho-physiology)

**Slim Jarboui** [\[PubMed\]](#)

Service de chirurgie generale, Hopital Rgional de Sidi Bouzid, **Tunisia** (General Surgery)

**Titus Sunday Ibekwe** [\[PubMed\]](#)

Department of Surgery(ENT), University of Abuja, **Nigeria** (Dentistry, Odontology)

**Houssine Boufetta** [\[PubMed\]](#)


University Hospital of Casablanca, Faculty of Medicine and Pharmacy of Casablanca, **Morocco** (Cancerology)

**Joyce Mumah** [\[PubMed\]](#)

International Planned Parenthood Federation, **Kenya** (Epidemiology, Community health)

**Peter Nsubuga** [\[PubMed\]](#)

Medical Epidemiology - Global Public Health Solutions, **United States** (Public Health, Epidemiology)

**Volume 44 (Jan - Apr 2023)**

## Research



# Expression of cytokeratin-7 and cytokeratin-19 on newborn mice induced rhesus rotavirus as biliary atresia model

Bagus Setyoboedi, Ahmad Rofii,  Anang Endaryanto, Sjamsul Arief

**Corresponding author:** Bagus Setyoboedi, Department of Child Health, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Hospital, Surabaya, Indonesia. bagus.setyoboedi@fk.unair.ac.id

**Received:** 16 Feb 2021 - **Accepted:** 25 Jul 2022 - **Published:** 31 Aug 2022

**Keywords:** Biliary atresia, cytokeratin-7, cytokeratin-19, mice model

**Copyright:** Bagus Setyoboedi et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Cite this article:** Bagus Setyoboedi et al. Expression of cytokeratin-7 and cytokeratin-19 on newborn mice induced rhesus rotavirus as biliary atresia model. Pan African Medical Journal. 2022;42(322). 10.11604/pamj.2022.42.322.28408

**Available online at:** <https://www.panafrican-med-journal.com//content/article/42/322/full>

## Expression of cytokeratin-7 and cytokeratin-19 on newborn mice induced rhesus rotavirus as biliary atresia model

Bagus Setyoboedi<sup>1,&</sup>, Ahmad Rofii<sup>1</sup>, Anang Endaryanto<sup>1</sup>, Sjamsul Arief<sup>1</sup>

<sup>1</sup>Department of Child Health, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Hospital, Surabaya, Indonesia

### &Corresponding author

Bagus Setyoboedi, Department of Child Health, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Hospital, Surabaya, Indonesia

## Abstract

**Introduction:** biliary atresia (BA) is a progressive inflammation that causes obstruction and fibro-obliteration of the bile ducts during the perinatal period. Biliary atresia occurs in about 1 in 5000 to 8000 live births, and 50% require liver transplantation. This study aims to investigate the influence of induction and duration of illness after rhesus rotavirus (RRV) exposure to changes in the expression of cytokeratin-7 (CK-7) and cytokeratin-19 (CK-19) in mice models of AB. **Methods:** a total of 48 Balb/c less than a day after birth was included as model of BA. The overall sample was split randomly by using the randomization table into 4

control groups and 4 treatment groups. Groups 1,2,3, and 4 composed of 24 infant mice Balb/c (each group of 6 tails) with blue color code get a placebo (buffered saline) intraperitoneally less than a day after birth. Groups 5, 6, 7, and 8 were composed of 24 mice Balb/c (each group of 6 tails) with red color code get induction RRV  $1.5 \times 10^6$  Plaque forming units (PFU) as treatment groups. **Results:** there are influence of the RRV induced changes in the expression of CK-7 murine model of BA day 3, 7, 14 and 21 after induction compared to the control ( $p < 0.05$ ). There was interaction between induction effects and duration of illness after RRV exposure to CK-7 expression in murine models of BA on days 3, 7, 14 and 21 ( $p < 0.001$ ). There was difference in the value of CK-19 expressions progressively between trial group and control group seen from day-3 and day 21. **Conclusion:** induction and duration of illness after rhesus rotavirus exposure effect on the expression of cytokeratin-7 and cytokeratin-19 mice models of biliary atresia.

## Introduction

Biliary atresia (BA) results from progressive inflammation. In BA, obstruction and fibro-obliteration of the intra and extrahepatic bile ducts occur during the perinatal period [1-3]. Biliary atresia occurs in about 1 in 5000 to 8000 live births, and 50% require liver transplantation [4,5]. The incidence of cholestatic jaundice is 1 in every 2,500 infants [6].

Biliary atresia's etiology remains uncertain. There are several factors thought to play a role in the pathogenesis of biliary atresia BA include infection, fetal circulatory disorders, abnormal morphogenesis, exposure to toxins, and immunological disorders [4,7,8]. Perinatal hepatobiliary viral infection will cause premature apoptosis or necrosis cholangiocyte if it lasts a chronic inflammatory process will lead to the total destruction of the bile ducts [7,9]. In BA, there is cell damage caused by an immunological response. In addition, there is a change in the characteristics of bile duct cells to those of mesenchymal cells.

Bile duct epithelial cells lose cell polarity, cell communication, loss of normal structure of epithelial cells accompanied by the accumulation of extracellular matrix (MES) [10-12]. This process is known as epithelial mesenchymal transition (EMT) [13-16]. In the process of EMT is characterized by decreased expression of calcium-dependent adhesion epithelial (E-cadherin), cytokeratin-7 (CK-7), cytokeratin-19 (CK - 19), integrins and increased expression of calcium-dependent adhesion neural (N-cadherin), vimetin, fibronectin,  $\alpha$  - smooth muscle actin ( $\alpha$ -SMA), fibroblast specific protein-1 (FSP-1) [17-19]. Studies in cell culture defined decreasing of epithelial cells markers such as cytokeratins and increasing of mesenchymal cells markers [20-22]. Liu (2013) found decreased expression of E cadherin and increased expression of N-cadherin (cadherin switch) day 6 after induction of TGF- $\beta$  in cell culture bile duct and De Vries (2011) found an increase in CK-7 and CK-19 day 7 and 14, but Taura (2010) in vitro did not get an increase in markers of mesenchymal cells [17,23,24]. The purpose of this study is to investigate the influence of induction and duration of illness after rhesus rotavirus (RRV) exposure to changes in the expression of CK-7 and CK-19 in mice models of AB.

## Methods

This research is purely experimental research using factorial design to investigate the influence of induction and duration of illness after rhesus rotavirus (RRV) exposure to changes in the expression of CK-7 and CK-19 in mice models of AB.

**Subject:** a total of 48 Balb/c less than a day after birth was included as model of BA. The overall sample was split randomly by using the randomization table into 4 control groups and 4 treatment groups. Groups 1,2,3, and 4 composed of 24 infant mice Balb/c (each group of 6 tails) with blue color code get a placebo (buffered saline) intraperitoneally less than a day after birth. Groups 5, 6, 7, and 8 were composed of 24 mice Balb/c (each group of 6 tails) with red color code get induction RRV  $1.5 \times 10^6$  PFU as treatment groups.

Inclusion criteria of Balb/c mice newborn from healthy carries, aged less than a day after birth startup research, and no any physical deformities. We excluded the baby mice born premature, and we drop out the mice with damage organs or tissues at the time of sampling for examination or the baby mice dead before age termination as specified. The control groups (O1) given 50  $\mu$ L buffered phosphate saline intraperitoneally less than a day after birth, then termination performed on the days 3, 7, 14 and 21, then checked the variables (P1-P4). Less than a day after birth, treatment groups (O2) were induced 50  $\mu$ L of phosphate buffered saline containing  $1.5 \times 10^6$  PFU RRV intraperitoneally. Furthermore randomly selected for termination performed on days 3, 7, 14, and 21, then examined the variables (P1-P4).

**Setting:** this research was conducted at the Laboratory of Biomolecular and Biomedical Laboratories, Faculty of Medicine, University of Brawijaya, Malang. The data collection of this research was conducted in January-February 2014.

**Data analysis:** analysis of the average for numerical data using mean and standard deviations (SD) of each variable with the independent sample t-test to the data with univariate normal distribution. For the results of the study were not normally distributed, the analysis performed by Mann Whitney test (for data with 2 groups) or Kruskal-Wallis (for data with >2 groups) for each group by using the median, respectively.

**Ethical clearance:** this study is part of a larger research entitled "benefits and the effect of corticosteroids on the difference between the expression of CD56, CD68, TLR, NFkB, CD4, CD8, ANCA, fibrosis and bile duct obstruction in animal model of biliary atresia (study changes in innate immune response, innate to adaptive non-self, adaptive non-self and adaptive self)" who has received information ethics from the Health Research Ethics Committee of the Faculty of Medicine, University of Brawijaya.

## Results

Basic characteristic of neonatal mice in each trial groups can be seen in Table 1. The baseline characteristics of weight initially homogeneous sample because the sample preparation in accordance with the inclusion criteria. However, in general there are differences in the mean body weight of mice when performed late termination (not included in the table). The increase in body weight of mice in the trial groups comparatively lower than the control groups for each day of termination. In this study, histopathological examination was also carried out to prove the occurrence of biliary atresia in mice induced RRV. Here is a comparison picture of the biliary tract histopathology qualitatively compared between the treatment groups to control groups (Figure 1, Figure 2, Figure 3 and Figure 4).

Induction RRV influence on expression of cytokeratin-7 and cytokeratin-19: from the expression of CK-7 and CK-19 biliary tract in the control groups of healthy mice that expresses all the variables studied, both CK-7 and CK-19. This suggests that the constitutive variables studied have been produced prior to the induction of RRV. To get an overview of the effect of RRV induced changes in the expression of CK-7 and CK-19, displayed the flow cytometry results in tabular form, all the results are arranged in the form of graphs that reflect the relative position of the two groups in each variable.

Induction RRV influence on expression of cytokeratin-7: in this study, a trial groups with a median value of expression of CK-7 quantitatively lower in the trial groups than the control groups with general results  $p < 0.05$ , which shows the influence of the RRV induced changes in the expression of CK-7 murine model of BA day 3, 7, 14 and 21 after induction compared to the control (Table 2). Also obtained results that are interaction between induction effects and duration of illness after RRV exposure to CK-7 expression in murine models of BA on days 3, 7, 14 and 21 with  $p < 0.001$  (Table 2).

The following chart changes in expression of CK-7 (median) from time to time in the control groups compare with trial groups (Figure 5). From the above chart, expression of CK-7 decreased in trial group since day 3 compared to control group. There was difference in the value of CK-7 expressions progressively between trial group and control group obtained from day-7 and the large difference in expression values obtained on day 21. The CK-7 expressions are lower in the trial group than control group.

Induction RRV influence on expression of cytokeratin-19: in this study, a trial groups with a median value of expression of CK-19 quantitatively lower in the trial groups than the control groups with general results  $p < 0.05$ , which shows the influence of the RRV induced changes in the expression of CK-19 murine model of BA day 3, 7, 14 and 21 after induction compared to the control (Table 3). Also obtained results that are interaction between induction effects and duration of illness after RRV exposure to CK-19 expressions in murine models of BA on days 3, 7, 14 and 21 with  $p < 0.001$  (Table 3).

The following chart changes in expression of CK-19 (median) from time to time in the control groups compare with trial groups (Figure 6). From the above chart, expression of CK-19 decreased in trial group since day 3 compared to control group. There is a progressive difference in the expression of CK-19 between the trial group and the control group obtained from day 3 and day 21. The CK-19 expressions are higher in trial group than control group. RRV induction dose of  $1.5 \times 10^6$  PFU intraperitoneally in infants Balb/c mice less than 1 day after birth would affect changes in cellular adaptive immune response in biliary tract tissue. In this study, the cellular adaptive immune response that occurs is reflected in the presence of expression of CK-7 and CK-19.

The hypothesis that pro-inflammatory cytokines important for the pathogenesis of BA has been tested on mice models induced RRV. Bile duct damage initiated by viral infection which is

followed by the release of antigens "self" that has changed and activate autoreactive T-cells and specific bile ducts, which causes chronic fibrosclerosing injury to the bile duct [4].

## Discussion

In this study, there were differences in mean final body weight (at termination) of mice in the control groups and trial groups. Newborn mice RRV-induced increased weight gain was relatively lower than control mice because of illness. Similarly, the mortality rate of mice in the trial groups occurs more frequently, especially before day 7 and between day 14 and 21. Mortality is caused by the baby mice looking sick and eaten by its parent in accordance with their nature. Baby mice that sick is most likely due to the induction of RRV as evidenced by the death of the trial groups more than the controls. These results are similar with Allen and Bessho, who obtained more than 80% of mice that have undergone RRV-induced biliary atresia on the 14<sup>th</sup> day of termination [25,26]. Petersen in his research got the lethality number reaches 100% in neonatal mice intervention after day 21 post-induction [27].

In this study, histopathological examination was done to prove the occurrence of inflammation and biliary tract obstruction as a result of an immunological response after induction of RRV. From the histopathology, inflammatory processes occurred from day 3 after induction of RRV were intensified on day 7. Obstruction process of biliary tract visible on day 14, and total obstruction seen at day 21. These results do not vary with Carvalho in which the inflammatory process in the biliary tract occurs on days 3 and 7 after induction of RRV, but he gets the total obstruction on day 14 [28]. Rhesus rotavirus infection in the biliary tract causing immunological dysregulation that results in inflammation of the duct epithelium and lumen of the duct becomes swollen. This inflammatory process is chronic and progressive because the autoimmune process that ended in the total obstruction of biliary tract and biliary tract cannot function properly. Rhesus rotavirus induction dose

of  $1.5 \times 10^6$  PFU intraperitoneally less than 1 day after birth in infants Balb/c mice would affect changes in cellular adaptive immune response in biliary tract tissue. In this study, the cellular adaptive immune response that occurs is reflected in the presence of expression of CK-7 and CK-19. The hypothesis that pro-inflammatory cytokines important for the pathogenesis of BA has been tested on mice models induced RRV. Bile duct damage initiated by viral infection which is characterized decrease CK-7 and CK-19.

**Cytokeratin-7 expressions:** this study is an experimental study with Balb/c mice which proves that RRV induction dose of  $1.5 \times 10^6$  PFU intraperitoneally at the age of less than 1 day after birth provides significant effect on the decrease in the expression of CK-7 when compared with controls and the decrease is going according to the time sequence begins after day 3 post-induction RRV.

In this study, decreased expression of CK-7 in experimental group compared to control group ( $p < 0.001$ ). The results of the study Harada (2009) with the dsRNA analog administration on bile duct epithelial cell cultures also have reduced expression of CK-7 as well Valdes (2002), Wistar rats were induced by TGF- $\beta$  that. There are differences in the expression of CK-7 were significantly ( $\Delta = 0.30$ ,  $p = 0.00$ ) between groups of families and groups try although the difference is not too big on day 3 [21,29]. On day 7 after induction of RRV also found decreased expression of CK-7 and expression differences greater than the control group ( $\Delta = 3.06$ ,  $p = 0.00$ ). These results are in accordance with the histopathology that showed an increase in inflammatory cells and bile duct lumen is narrower. Erickson (2008) also got mild to moderate obstruction and inflammation around the bile ducts in the preparation of histopathological on day 7 [30].

Choi (2009) found the lowest value CK-7 expressions at day 7 after administration of CCl<sub>4</sub> in intraperitoneal in mice. Increased expression of this cytokeratins according to De Vries (2011) caused

the entire cell stress induced RRV and some cells undergo phenotypic changes, especially for the formation of connective tissue, whereas the expression of CK-7 and CK-19 were decreased [24,31]. On day 14 the expression values obtained difference between experimental and control group greater ( $\Delta = 10.6$ ,  $p = 0.00$ ) and on day 21 the greatest decrease obtained in this study ( $\Delta = 17.5$ ,  $p = 0.00$ ). This phenomenon indicates that the longer the exposure after induction of RRV, epithelial cell damage or apoptosis, fibrosis and EMT that occurs more widely. In the histopathological results obtained biliary tract total obstruction on 21<sup>st</sup> day. These results corresponded to Feng's (2005) gain on day 21 of total obstruction extrahepatic bile duct after induction RRV [32].

Cytokeratin-7 expressions from day 3 until day 21 had an upward trend despite the lower expression values when compared with control group. This could be because the baby bulb/c is still in a growth phase so that the process of epithelialization occurs for the growth of tissues and organs as well as for cell regeneration. In bulb/c infants, the given induction RRV also in the maturity phase of growth for organ function and regeneration of cells, although the value is lower than the control group therefore occur RRV-induced inflammatory process so that the process of epithelialization of epithelial cells disrupted by inflammation, apoptosis and changes into mesenchymal cells. The difference in the value of CK-7 expressions on experimental group apoptosis and cell survival changes the phenotype of epithelial cells into mesenchymal cells accompanied by activation of fibroblasts as a result of inflammatory responses by induction of RRV.

**Cytokeratin-19 expression:** in this study, gain reduction the expression of CK-19 in experimental group ( $p < 0.001$ ) and the longer the exposure time, the virus was also found reduced expression of CK-19 greater than the experimental group than the control group. Harada (2009) found that after administration of the dsRNA analog bile duct epithelial cell culture, a decline in CK-19 and other markers of epithelial cells and an increase in

markers - markers of mesenchymal cells, such as FSP-1 and vimentin [21]. On the third day there is a decrease in the expression of CK-19 significant ( $\Delta = 1.1$ ;  $p = 0.007$ ) between the groups. On day 7 obtained the lowest decline and greatest expression differences CK-19 among experimental group compared to control group ( $\Delta = 13.9$ ;  $p = 0.000$ ). Yabushita (2001) found a decrease in the expression of CK-19 since day 3 in rats induced RRV. De Vries (2011) found that difference expression of CK-19 were increased compared to control on day 7, results this is supported by the increased expression of mesenchymal cell markers such as  $\alpha$ -SMA [24,33].

Increased expression of CK-19 at experimental group happened from day 14 ( $\Delta = 10.8$ ;  $p = 0.000$ ) and continued on day 21 although it remained below the pattern control group ( $\Delta = 7.6$ ;  $p = 0.000$ ). Histopathological results at day 14 showed that the distribution of inflammatory cells reached a maximum and on day 21 had occurred total obstruction biliary tract. This research is in accordance with Paku (2005) which says that although there has been a total blockage on histopathologic examination, however CK-19 can still be detected on flow cytometry examination [14,17,21].

In the EMT process biliary atresia besides a decline in the expression of CK-7 and CK-19, obtained also a decrease other markers of epithelial cells (E-cadherin) and an increase in markers of mesenchymal cells such as N-cadherin vimentin, FSP-1,  $\alpha$ -SMA, fibronectin [10,13,20,21,29]. In biliary atresia EMT process, in addition to decrease expression of CK-19 and other epithelial cell markers, also found an increasing in the expression of mesenchymal cells (vimentin, FSP-1,  $\alpha$ -SMA, collagen type 1, fibronectin). And in normal mammalian life, mesenchymal cells will always be formed to establish and maintain the integrity of connective tissue organs and tissues [34].

## Conclusion

The results of this study provide additional evidence of the truth of the hypothesis that the induction of RRV resulted in changes the expression of cytokeratin-7 and cytokeratin-19 in the pathogenesis of BA, thus opening discourse to do further studies for new strategies in the management of medically BA. Progressive decrease expression of cytokeratin-7 and cytokeratin-19 beginning on day 7 with a peak at day 21 shows that the possibility of a good time for medical intervention performed around day 7 and before day 14, because after day 14, the occurrence of BA already irreversible.

### **What is known about this topic**

- *Biliary atresia (BA) is a progressive inflammatory obstruction in bile ducts during the perinatal period;*
- *Etiology of biliary atresia is still unclear;*
- *In biliary atresia, there are decreased expression of calcium-dependent adhesion epithelial (E-cadherin), cytokeratin-7 (CK-7), and cytokeratin-19 (CK-19).*

### **What this study adds**

- *There is influence of the RRV induced changes in the expression of CK-7 murine model of BA day 3, 7, 14 and 21 after induction compared to the control;*
- *There are interaction between induction effects and duration of illness after RRV exposure to CK-7 expressions in murine models of BA on days 3, 7, 14 and 21;*
- *Induction and duration of illness after rhesus rotavirus exposure effect on the expression of cytokeratin-7 and cytokeratin-19 mice models of biliary atresia.*

## Competing interests

The authors declare no competing interests.

## Authors' contributions

Bagus Setyoboedi conceived and designed analysis, collect the data, contributed data and analysis tool, performed the analysis, drafted and wrote the article, and final approval of the version to be published; Ahmad Rofii collected the data, contributed data and analysis tool, performed the analysis, drafted and wrote the article, and final approval of the version to be published; Anang Endaryanto and Sjamsul Arief contributed data and analysis tool, final approval of the version to be published. All the authors have read and agreed to the final manuscript.

## Tables and figures

**Table 1:** sample characteristics

**Table 2:** changes in the expression of cytokeratin-7 in the RRV induction groups and control groups

**Table 3:** changes in the expression of cytokeratin-19 in the RRV induction groups and control groups

**Figure 1:** histological slices of liver and biliary tract tissues of infant mice after termination day 3; A) control groups: no visible presence of inflammatory cells in the lumen of the bile duct with no narrowing (black arrow); B) treatment groups: visible infiltration of inflammatory cells accompanied by swelling of the lumen of the bile duct that causes ranging narrowed lumen (black arrow) (bPV: branch of portal vein, bHA: branch of hepatic artery)

**Figure 2:** histological slices of liver and biliary tract tissues of infant mice after termination day 7; A) control groups: no visible presence of inflammatory cells in the lumen of the bile duct with no narrowing (black arrow); B) treatment groups: visible infiltration of inflammatory cells that multiply the lumen of the bile duct causing swelling that result in increased narrow lumen (black arrow) compared to day 3 (bPV: branch of portal vein, bHA: branch of hepatic artery)

**Figure 3:** histological slices of liver and biliary tract tissues of mice after termination day 14; A) control groups: no visible presence of inflammatory cells in the lumen of the bile duct with no narrowing (black

arrow); B) treatment groups: visible infiltration a lot of inflammatory cells that cause swelling and the lumen of the bile ducts become clogged lumen (black arrow) (bPV: branch of portal vein, bHA: branch of hepatic artery)

**Figure 4:** histological slices of liver and biliary tract tissues of mice after termination day 21; A) control groups: no visible presence of inflammatory cells in the lumen of the bile duct with no narrowing (black arrow); B) treatment groups: visible lumen of the bile duct has undergone atresia (black arrows) (bPV: branch of portal vein, bHA: branch of hepatic artery)

**Figure 5:** effect of induction of RRV and duration of illness after RRV exposure to changes in the expression of cytokeratin - 7 (median) compared to the control groups

**Figure 6:** effect of induction of RRV and duration of illness after RRV exposure to changes in the expression of cytokeratin - 19 (median) compared to the control groups

## References

1. Balistreri WF, Grand R, Hoofnagle JH, Suchy FJ, Ryckman FC, Perlmutter DH *et al.* Biliary atresia: current concepts and research directions. *Hepatology.* 1996;23(6): 1682-1692. [PubMed](#) | [Google Scholar](#)
2. Bezerra JA. Potential etiologies of biliary atresia. *Pediatr Transplant.* 2005 Oct;9(5): 646-51. [PubMed](#) | [Google Scholar](#)
3. Hadzic N. Biliary atresia. *Acta Medica Academica.* 2009;38: 92-103. [Google Scholar](#)
4. Kahn E. Biliary atresia revisited. *Pediatr Dev Pathol.* 2004 Mar-Apr;7(2): 109-24. [PubMed](#) | [Google Scholar](#)
5. Hartley JL, Davenport M, Kelly DA. Biliary atresia. *Lancet.* 2009;374(9702): 1704-13. [PubMed](#) | [Google Scholar](#)
6. Feldman AG, Sokol RJ. Neonatal cholestasis. *Neoreviews.* 2013 Feb 1;14(2): 10. [PubMed](#) | [Google Scholar](#)

7. Mack CL. The pathogenesis of biliary atresia: evidence for a virus induced autoimmune disease. *Semin Liver Dis.* 2007;27(3): 233-242. **PubMed** | **Google Scholar**
8. Basset MD, Murray KF. Biliary atresia recent progress. *J Clin Gastroenterol.* 2008 Jul;42(6): 720-9. **PubMed** | **Google Scholar**
9. Shivakumar P, Campbell KM, Sabla GE, Miethke A, Tiao G, McNeal MM *et al.* Obstruction of extrahepatic bile ducts by lymphocytes is regulated by IFN- $\gamma$  in experimental biliary atresia. *J Clin Invest.* 2004;114(3): 322-329. **PubMed** | **Google Scholar**
10. Díaz R, Kimf JW, Hui J, Li Z, Swain GP, Fong K *et al.* Evidence for the epithelial to mesenchymal transition in biliary atresia fibrosis. *Hum Pathol.* 2008 Jan;39(1): 102-15. **PubMed** | **Google Scholar**
11. Greenbaum LE. Hedgehog signaling in biliary fibrosis. *J Clin Invest.* 2008;118(10): 3263-3265. **PubMed** | **Google Scholar**
12. Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA *et al.* Epithelial mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. *Lab Invest.* 2008;88(2): 112-123. **PubMed** | **Google Scholar**
13. Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, Choi SS *et al.* Hedgehog signaling regulates epithelialmesenchymal transition during biliary fibrosis in rodents and humans. *J Clin Invest.* 2008;118(10): 3331-3342. **PubMed** | **Google Scholar**
14. Park SM. The crucial role of cholangiocytes in cholangiopathies. *Gut Liver.* 2012;6(3): 295-304. **PubMed** | **Google Scholar**
15. Xu J, Lamouille S, Derynck R. TGF- $\beta$ -induced epithelial to mesenchymal transition. *Cell Res.* 2009 Feb;19(2): 156-72. **PubMed** | **Google Scholar**
16. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H *et al.* Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. *J Biol Chem.* 2007 Aug 10;282(32): 23337-47. **PubMed** | **Google Scholar**
17. Lee K, Nelson CM. New insight into the regulation of epithelial mesenchymal transition and tissue fibrosis. *Int Rev Cell Mol Biol.* 2012;294: 171-221. **PubMed** | **Google Scholar**
18. Kalluri R. EMT: when epithelial cells decide to become mesenchymal like cells. *J Clin Invest.* 2009 Jun;119(6): 1417-9. **PubMed** | **Google Scholar**
19. Wells RG. Epithelial to mesenchymal transition in liver fibrosis: here today, gone tomorrow? *Hepatology.* 2010;51(3): 737-740. **PubMed** | **Google Scholar**
20. Sato Y, Harada K, Ozaki S, Furubo S, Kizawa K, Sanzen T *et al.* Cholangiocytes with mesenchymal features contribute to progressive hepatic fibrosis of the polycystic kidney rat. *Am J Pathol.* 2007;171(6): 1859-1871. **PubMed** | **Google Scholar**
21. Harada K, Sato Y, Ikeda H, Isse K, Ozaki S, Enomae M *et al.* Epithelial mesenchymal transition induced by biliary innate immunity contributes to the sclerosing cholangiopathy of biliary atresia. *J Pathol.* 2009 Apr;217(5): 654-64. **PubMed** | **Google Scholar**
22. Deng YH, Pu CL, Li YC, Zhu J, Xiang C, Zhang MM *et al.* Analysis of biliary epithelial-mesenchymal transition in portal tract fibrogenesis in biliary atresia. *Dig Dis Sci.* 2011 Mar;56(3): 731-40. **PubMed** | **Google Scholar**
23. Taura K, Miura K, Iwaisako K, Osterreicher CH, Kodama Y, Penz-Osterreicher M *et al.* Hepatocytes do not undergo epithelial mesenchymal transition in liver fibrosis in mice. *Hepatology.* 2010 Mar;51(3): 1027-36. **PubMed** | **Google Scholar**
24. De Vries W. Bile duct proliferation and hedgehog signaling in murine biliary atresia: a pilot study. Degree of Master in University Medical Center Groningen. Groningen. 2011.
25. Allen SR, Jafri M, Donnelly B, McNeal M, Witte D, Bezerra J *et al.* Effect of rotavirus strain on the murine model of biliary atresia. *J Virol.* 2007;81(4): 1671-1679. **PubMed** | **Google Scholar**

26. Bessho K, Bezerra JA. Biliary atresia: Will blocking inflammation tame the disease? *Annu Rev Med.* 2011;62: 171-185. **PubMed** | **Google Scholar**
27. Petersen C, Grassholl S, Luciano L. Diverse morphology of biliary atresia in an animal model. *J Hepatol.* 1998 Apr;28(4): 603-7. **PubMed** | **Google Scholar**
28. Carvalho E, Liu C, Shivakumar P, Sabla G, Aronow B, Bezerra JA. Analysis of the biliary transcriptome in experimental biliary atresia. *Gastroenterology.* 2005;129(2): 713-717. **PubMed** | **Google Scholar**
29. Valdes F, Alvarez AM, Locascio A, Vega S, Herrera B, Fernandez M *et al.* The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor  $\beta$  in fetal rat hepatocytes. *Mol Cancer Res.* 2002 Nov;1(1): 68-78. **PubMed** | **Google Scholar**
30. Erickson N, Mohanty SK, Shivakumar P, Sabla G, Chakraborty R, Bezerra JA. Temporal spatial activation of apoptosis and epithelial Injury in murine experimental biliary atresia. *Hepatology.* 2008;47(5): 1567-77. **PubMed** | **Google Scholar**
31. Choi SS, Diehl AM. Epithelial to mesenchymal transitions in the liver. *Hepatology.* 2009;50(6): 2007-2013. **PubMed** | **Google Scholar**
32. Feng J, Lia M, Caib T, Tang H, Gu W. Rotavirus induced murine biliary atresia is mediated by nuclear factor- $\kappa$ B. *J Pediatr Surg.* 2005 Apr;40(4): 630-6. **PubMed** | **Google Scholar**
33. Yabushita K, Yamamoto K, Ibuki N, Okano N, Matsumura S, Okamoto R *et al.* Aberrant expression of cytokeratin - 7 as a histological marker of progression in primary biliary cirrhosis. *Liver.* 2001;21(1): 50-55. **PubMed** | **Google Scholar**
34. Nakaya Y, Sheng G. Epithelial to mesenchymal transition during gastrulation: an embryological view. *Dev Growth Differ.* 2008 Dec;50(9): 755-66. **PubMed** | **Google Scholar**

**Table 1:** sample characteristics

Day	Control groups				Trial groups			
	3	7	14	21	3	7	14	21
Number of groups	6	6	6	6	6	6	6	6
Mean early BW (g)	1.84	1.82	1.80	1.81	1.85	1.83	1.80	1.82
Drop out	2	0	0	0	2	2	1	2
Total samples	4	6	6	6	4	4	5	4

BW: body weight

**Table 2:** changes in the expression of cytokeratin-7 in the RRV induction groups and control groups


Variable	Day	Control groups	Trial groups	p* between groups per variables
		Median (interquartil)	Median (interquartil)	
CK - 7	3	4.5 (0.06) %	4.2 (0.05) %	0.00*
	7	6.9 (0.15) %	3.9 (0.10) %	0.00*
	14	20.8% (0.08) %	10.2 (3.22) %	0.00*
	21	25.2 (0.63)%	7.7 (0.71) %	0.00*
	p*	0.000**	0.02**	

\*significant differences by Mann Whitney test at  $\alpha=0.05$ ; \*\* significant differences by Kruskal Wallis test at  $\alpha=0.05$


**Table 3:** changes in the expression of cytokeratin-19 in the RRV induction groups and control groups

Variable	Day	Control groups Median (interquartil)	Trial groups Median (interquartil)	p* between groups per variables
CK - 19	3	6.4 (0.64) %	5.3 (0.06) %	0.007***
	7	18.2 (0.14) %	4.3 (0.09) %	0.000*
	14	19.4 (1.02) %	8.6 (1.59) %	0.000*
	21	23.3 (0.06) %	15.7 (0.71)%	0.000*
	p	<0.000**	0.002**	


\*significant differences by Mann Whitney test at  $\alpha < 0.05$ ; \*\* significant differences by Kruskal Wallis test at  $\alpha < 0.05$ ; \*\*\* significant differences by T-Test at  $p < 0.05$




**Figure 1:** histological slices of liver and biliary tract tissues of infant mice after termination day 3; A) control groups: no visible presence of inflammatory cells in the lumen of the bile duct with no narrowing (black arrow); B) treatment groups: visible infiltration of inflammatory cells accompanied by swelling of the lumen of the bile duct that causes ranging narrowed lumen (black arrow) (bPV: branch of portal vein, bHA: branch of hepatic artery)



**Figure 2:** histological slices of liver and biliary tract tissues of infant mice after termination day 7; A) control groups: no visible presence of inflammatory cells in the lumen of the bile duct with no narrowing (black arrow); B) treatment groups: visible infiltration of inflammatory cells that multiply the lumen of the bile duct causing swelling that result in increased narrow lumen (black arrow) compared to day 3 (bPV: branch of portal vein, bHA: branch of hepatic artery)




**Figure 3:** histological slices of liver and biliary tract tissues of mice after termination day 14; A) ontrol groups: no visible presence of inflammatory cells in the lumen of the bile duct with no narrowing (black arrow); B) treatment groups: visible infiltration a lot of inflammatory cells that cause swelling and the lumen of the bile ducts become clogged lumen (black arrow) (bPV: branch of portal vein, bHA: branch of hepatic artery)




**Figure 4:** histological slices of liver and biliary tract tissues of mice after termination day 21; A) control groups: no visible presence of inflammatory cells in the lumen of the bile duct with no narrowing (black arrow); B) treatment groups: visible lumen of the bile duct has undergone atresia (black arrows) (bPV: branch of portal vein, bHA: branch of hepatic artery)

### CK-7



**Figure 5:** effect of induction of RRV and duration of illness after RRV exposure to changes in the expression of cytokeratin - 7 (median) compared to the control groups

## CK-19



**Figure 6:** effect of induction of RRV and duration of illness after RRV exposure to changes in the expression of cytokeratin - 19 (median) compared to the control groups